JY
LKFT

Jeff Yass’s Lakefront Biotherapeutics American Depositary Shares LKFT Stock Holding History

Jeff Yass’s Portfolio LKFT Stock Details LKFT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-95,700
Closed -$2.4M – 13033
2025
Q1 		$2.4M Sell
95,700
-10,600
-10% -$268K ﹤0.01% 5121
2024
Q4 		$2.92M Buy
106,300
+54,800
+106% +$1.53M ﹤0.01% 4527
2024
Q3 		$1.48M Buy
+51,500
New +$1.4M ﹤0.01% 5936
2024
Q2 		– Sell
-25,500
Closed -$821K – 12463
2024
Q1 		$821K Sell
25,500
-29,300
-53% -$1.09M ﹤0.01% 7354
2023
Q4 		$2.23M Buy
54,800
+38,400
+234% +$1.41M ﹤0.01% 5131
2023
Q3 		$567K Buy
+16,400
New +$638K ﹤0.01% 7935
2023
Q2 		– Sell
-34,300
Closed -$1.33M – 12455
2023
Q1 		$1.33M Sell
34,300
-1,300
-4% -$53.4K ﹤0.01% 6105
2022
Q4 		$1.58M Buy
35,600
+29,000
+439% +$1.22M ﹤0.01% 5167
2022
Q3 		$281K Sell
6,600
-87,400
-93% -$4.48M ﹤0.01% 9956
2022
Q2 		$5.25M Buy
94,000
+29,200
+45% +$1.73M ﹤0.01% 3109
2022
Q1 		$4.02M Buy
64,800
+47,800
+281% +$2.93M ﹤0.01% 4056
2021
Q4 		$937K Buy
17,000
+8,800
+107% +$459K ﹤0.01% 7479
2021
Q3 		$431K Sell
8,200
-17,500
-68% -$1.04M ﹤0.01% 9759
2021
Q2 		$1.77M Sell
25,700
-10,700
-29% -$816K ﹤0.01% 6198
2021
Q1 		$2.81M Sell
36,400
-6,400
-15% -$590K ﹤0.01% 5115
2020
Q4 		$4.24M Sell
42,800
-6,500
-13% -$795K ﹤0.01% 3698
2020
Q3 		$7M Sell
49,300
-5,000
-9% -$834K ﹤0.01% 2648
2020
Q2 		$10.7M Sell
54,300
-149,400
-73% -$30.9M ﹤0.01% 2051
2020
Q1 		$39.9M Buy
203,700
+175,100
+612% +$37.7M 0.01% 763
2019
Q4 		$5.92M Sell
28,600
-27,300
-49% -$5.05M ﹤0.01% 2746
2019
Q3 		$8.53M Buy
55,900
+6,300
+13% +$1.03M ﹤0.01% 2145
2019
Q2 		$6.39M Sell
49,600
-166,300
-77% -$19.7M ﹤0.01% 2400
2019
Q1 		$25.4M Buy
215,900
+204,700
+1,828% +$20.6M 0.01% 1016
2018
Q4 		$1.03M Sell
11,200
-12,500
-53% -$1.27M ﹤0.01% 4613
2018
Q3 		$2.67M Buy
23,700
+12,500
+112% +$1.32M ﹤0.01% 3545
2018
Q2 		$1.03M Sell
11,200
-1,300
-10% -$126K ﹤0.01% 5286
2018
Q1 		$1.25M Buy
+12,500
New +$1.35M ﹤0.01% 4798
2017
Q4 		– Sell
-2,000
Closed -$204K – 9475
2017
Q3 		$204K Sell
2,000
-1,300
-39% -$114K ﹤0.01% 7986
2017
Q2 		$253K Buy
+3,300
New +$278K ﹤0.01% 7882

Other funds holding LKFT

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
DCM
DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Jeff Yass's LKFT Position: Q2 2026 in Review

Jeff Yass increased its Lakefront Biotherapeutics American Depositary Shares (LKFT) stake by 1,035% in Q2 2026, buying an estimated $3.93M and bringing the position to 151,886 shares worth $4.55M. The position accounts for ﹤0.01% of the portfolio, ranked #4802.

Jeff Yass first reported a position in LKFT in Q3 2016 and has held it in 30 quarters since. The position peaked at $8.58M in Q1 2021. 77 funds tracked by Wall St. Rank hold LKFT as of Q2 2026.

  • Jeff Yass held 151,886 shares of Lakefront Biotherapeutics American Depositary Shares worth $4.55M as of Q2 2026.
  • Jeff Yass bought 138,499 Lakefront Biotherapeutics American Depositary Shares shares in Q2 2026, an estimated $3.93M.
  • Lakefront Biotherapeutics American Depositary Shares made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4802 holding.
  • Jeff Yass first reported a position in Lakefront Biotherapeutics American Depositary Shares in Q3 2016 and has held it in 30 quarters since.
  • Jeff Yass's Lakefront Biotherapeutics American Depositary Shares position peaked at $8.58M in Q1 2021.
  • 77 funds tracked by Wall St. Rank held Lakefront Biotherapeutics American Depositary Shares as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.